Chief of Staff
ITF Therapeutics
Chief of Staff
ITF Therapeutics
Develops and commercializes rare-disease therapies
About This Role:
Reporting to the President of ITF Therapeutics US, the Chief of Staff will operate at the center of ITF Therapeutics, serving as a strategic thought partner to the President and an integrator across the leadership team. The Chief of Staff will help shape enterprise priorities, improve the quality and speed of decision-making, translate strategy into coordinated execution, and continuously evolve the operating model as ITF scales into a rare disease portfolio company that make a positive contribution to a range of patient communities.
This is a broad, highly visible role requiring equal strength in strategy, execution, and organizational savvy. The successful candidate will be comfortable framing ambiguous problems, challenging and influencing senior leaders, navigating a global/local matrix, and moving fluidly between enterprise-level strategic questions and hands-on execution. The Chief of Staff will work across functions without displacing functional ownership, stepping in where issues span organizational boundaries, ownership is unclear, or additional enterprise leadership is required.
What You'll Do:
Strategic & Executive Partnership
Enterprise Strategy & Planning
Business Performance & Enterprise Execution
Governance & Organizational Effectiveness
Enterprise Integration & Stakeholder management
Required Skills:
Preferred Skills:
Additional Information:
The base compensation range for this role is: $270,000 - $295,000. Compensation is determined through an analytical approach utilizing a combination of factors including, but not limited to, relevant skills & experience, job location, and internal equity.
Develops and commercializes rare-disease therapies
ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.
Explore more opportunities at ITF Therapeutics